Two clinical trials of SARS CoV-2 adenovirus-based vaccines have been temporarily halted due to autoimmune complications concerns in some participants. Similarly, though the innovative SARS CoV-2 RNA based vaccines when approved to combat the current COVID-19 pandemic would be considered first of their kind, they also possess potential risks including development of autoimmune diseases. The techniques used in development of these types of vaccines should focus on the methods to decrease their

more »

... tential autoimmunity. Smokers, obese and diabetic individuals are more liable groups to develop autoimmune diseases and we recommend a personalized risk benefit ratio to be evaluated before vaccination waiting for the post marketing surveillance. Further, quitting smoking, loss of overweight and control of blood glucose levels might help to lower their probabilities.